Sandbox:Sara: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 2: Line 2:


{{CMG}}; {{AE}} {{S.M.}}
{{CMG}}; {{AE}} {{S.M.}}
*Treatment includes:<ref name="pmid31251395">{{cite journal| author=Huis In 't Veld EA, van Houdt WJ| title=Reply to Follow-up after treatment of dermatofibrosarcoma protuberans. | journal=Cancer | year= 2019 | volume=  | issue=  | pages=  | pmid=31251395 | doi=10.1002/cncr.32341 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31251395  }} </ref><ref name="pmid16416612">{{cite journal| author=Loss L, Zeitouni NC| title=Management of scalp dermatofibrosarcoma protuberans. | journal=Dermatol Surg | year= 2005 | volume= 31 | issue= 11 Pt 1 | pages= 1428-33 | pmid=16416612 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16416612  }} </ref><ref name="pmid8646467">{{cite journal| author=Dawes KW, Hanke CW| title=Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. | journal=Dermatol Surg | year= 1996 | volume= 22 | issue= 6 | pages= 530-4 | pmid=8646467 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8646467  }} </ref><ref name="pmid10870053">{{cite journal| author=Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM et al.| title=Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. | journal=Cancer | year= 2000 | volume= 88 | issue= 12 | pages= 2711-20 | pmid=10870053 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10870053  }} </ref><ref name="pmid14983497">{{cite journal| author=DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK| title=Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. | journal=Cancer | year= 2004 | volume= 100 | issue= 5 | pages= 1008-16 | pmid=14983497 | doi=10.1002/cncr.20051 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14983497  }} </ref><ref name="pmid15221986">{{cite journal| author=Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB| title=Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. | journal=Cancer | year= 2004 | volume= 101 | issue= 1 | pages= 28-38 | pmid=15221986 | doi=10.1002/cncr.20316 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15221986  }} </ref>
*[[Treatments|Treatment]] includes:<ref name="pmid31251395">{{cite journal| author=Huis In 't Veld EA, van Houdt WJ| title=Reply to Follow-up after treatment of dermatofibrosarcoma protuberans. | journal=Cancer | year= 2019 | volume=  | issue=  | pages=  | pmid=31251395 | doi=10.1002/cncr.32341 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31251395  }} </ref><ref name="pmid16416612">{{cite journal| author=Loss L, Zeitouni NC| title=Management of scalp dermatofibrosarcoma protuberans. | journal=Dermatol Surg | year= 2005 | volume= 31 | issue= 11 Pt 1 | pages= 1428-33 | pmid=16416612 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16416612  }} </ref><ref name="pmid8646467">{{cite journal| author=Dawes KW, Hanke CW| title=Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins. | journal=Dermatol Surg | year= 1996 | volume= 22 | issue= 6 | pages= 530-4 | pmid=8646467 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8646467  }} </ref><ref name="pmid10870053">{{cite journal| author=Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM et al.| title=Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. | journal=Cancer | year= 2000 | volume= 88 | issue= 12 | pages= 2711-20 | pmid=10870053 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10870053  }} </ref><ref name="pmid14983497">{{cite journal| author=DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK| title=Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. | journal=Cancer | year= 2004 | volume= 100 | issue= 5 | pages= 1008-16 | pmid=14983497 | doi=10.1002/cncr.20051 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14983497  }} </ref><ref name="pmid15221986">{{cite journal| author=Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB| title=Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. | journal=Cancer | year= 2004 | volume= 101 | issue= 1 | pages= 28-38 | pmid=15221986 | doi=10.1002/cncr.20316 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15221986  }} </ref>
** Imatinib-STI571 (tyrosine kinase inhibitor) therapy (may be effective in CD117- tumors) is the gold standard treatment of recurrent or inoperable tumor
 
** Excisional sugery including the removal of subcutaneous fat (i.e. wide local excision with 2 - 3 cm margins) alongwith 3-dimensional histologic evaluation of margins is necessarily recommended in order to prevent the tumor recurrence
{| class="wikitable"
*Treatment is primarily [[surgical]], with [[chemotherapy]] and [[radiation therapy]] sometimes being used. 
|+Treatment options for dermatofibrosarcoma protuberans
*There is clinical evidence that [[imatinib]], which inhibits PDGFB, may be effective for tumors positive for the t(17;22) translocation.
!Treatment option
!Details
|-
|'''[[Surgery]]'''
|
*[[Mohs micrographic surgery]]
*[[Excision repair|Excisional]] [[surgery]] includes:
**Removal of [[subcutaneous fat]] (i.e. [[Wide and fast|wide]] [[local]] [[excision]] with 2 - 3 [[Centimetre|cm]] margins)
**3-[[Dimensional analysis|dimensional]] [[histological]] evaluation of margins (necessarily recommended in order to [[Prevention (medical)|prevent]] the [[tumor]] [[Recurrence plot|recurrence]])
|-
|[[Targeted therapy|'''Targeted therapy''']]
|
* [[Imatinib]]-[[STI571]] ([[tyrosine kinase inhibitor]]) [[therapy]] (may be [[Effective method|effective]] in [[CD117]]- [[tumors]]) is the [[Gold standard (test)|gold standard]] [[Treatments|treatment]] of [[Recurrence plot|recurrent]] or [[inoperable]] [[tumor]]
* As [[imatinib]] [[Inhibition|inhibits]] [[PDGFB]], may be [[Effective method|effective]] for [[tumors]] positive for the t(17;22) [[Translocations|translocation]]
|-
|'''[[Chemotherapy]]'''
|
* Less beneficial than [[targeted therapy]]
|-
|'''[[Radiotherapy]]'''
|
* May be required sometimes
|}


==Reference==
==Reference==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 16:52, 16 August 2019


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Treatment options for dermatofibrosarcoma protuberans
Treatment option Details
Surgery
Targeted therapy
Chemotherapy
Radiotherapy
  • May be required sometimes

Reference

  1. ↑ Huis In 't Veld EA, van Houdt WJ (2019). "Reply to Follow-up after treatment of dermatofibrosarcoma protuberans". Cancer. doi:10.1002/cncr.32341. PMID 31251395.
  2. ↑ Loss L, Zeitouni NC (2005). "Management of scalp dermatofibrosarcoma protuberans". Dermatol Surg. 31 (11 Pt 1): 1428–33. PMID 16416612.
  3. ↑ Dawes KW, Hanke CW (1996). "Dermatofibrosarcoma protuberans treated with Mohs micrographic surgery: cure rates and surgical margins". Dermatol Surg. 22 (6): 530–4. PMID 8646467.
  4. ↑ Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM; et al. (2000). "Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution". Cancer. 88 (12): 2711–20. PMID 10870053.
  5. ↑ DuBay D, Cimmino V, Lowe L, Johnson TM, Sondak VK (2004). "Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution". Cancer. 100 (5): 1008–16. doi:10.1002/cncr.20051. PMID 14983497.
  6. ↑ Snow SN, Gordon EM, Larson PO, Bagheri MM, Bentz ML, Sable DB (2004). "Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature". Cancer. 101 (1): 28–38. doi:10.1002/cncr.20316. PMID 15221986.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:Sara&oldid=1579923"